 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | FLU-IGIV / Emergent Biosolutions
Preclinical, Journal: Efficacy of anti-influenza immunoglobulin (FLU-IGIV) in ferrets and mice infected with 2009 pandemic influenza virus. (Pubmed Central) - Jul 18, 2021
FLU-IGIV significantly reduced the viral load in the lungs compared to placebo (PBS) in ferrets infected with influenza A/California/July 2009 (H1N1pdm09) virus. Overall, these studies demonstrate the efficacy of human plasma-derived FLU-IGIV in relevant animal models of influenza virus infection.
- FLU-IGIV / Emergent Biosolutions
[VIRTUAL] Anti-influenza immunoglobulin (FLU-IVIG) in hospitalised patients with serious influenza A () - May 20, 2021 - Abstract #ECCMID2021ECCMID_3414;
FLU-IGIV reduced time to hospital discharge and was associated with better outcomes at Day 4 . Further studies are warranted to confirm these data.
- | FLU-IGIV / Emergent Biosolutions
Trial completion: Exploring Safety & Clinical Benefit of Anti-Influenza Immunoglobulin Intravenous in Hospitalized Adults With Influenza A (clinicaltrials.gov) - Jul 15, 2019
P2, N=65, Completed, Sponsor: Emergent BioSolutions
Further studies are warranted to confirm these data. Recruiting --> Completed
- || FLU-IGIV / Emergent Biosolutions
Trial completion date, Trial primary completion date: Exploring Safety & Clinical Benefit of Anti-Influenza Immunoglobulin Intravenous in Hospitalized Adults With Influenza A (clinicaltrials.gov) - Jun 20, 2018
P2, N=75, Recruiting, Sponsor: Emergent BioSolutions
Recruiting --> Completed Trial completion date: Jun 2018 --> Jun 2019 | Trial primary completion date: Jun 2018 --> Jun 2019
- |||| FLU-IGIV / Emergent Biosolutions
Enrollment open: Exploring Safety & Clinical Benefit of Anti-Influenza Immunoglobulin Intravenous in Hospitalized Adults With Influenza A (clinicaltrials.gov) - Nov 24, 2017
P2, N=75, Recruiting, Sponsor: Emergent BioSolutions
Trial completion date: Jun 2018 --> Jun 2019 | Trial primary completion date: Jun 2018 --> Jun 2019 Not yet recruiting --> Recruiting
- ||||| FLU-IGIV / Emergent Biosolutions
New P2 trial: Exploring Safety & Clinical Benefit of Anti-Influenza Immunoglobulin Intravenous in Hospitalized Adults With Influenza A (clinicaltrials.gov) - Oct 19, 2017
P2, N=75, Not yet recruiting, Sponsor: Emergent BioSolutions